The FDA said it has identified 76 cases of drug-induced liver injuries with reasonable evidence of being causally linked to ...

March 31 (Reuters) - The U.S. Food and Drug Administration on Monday said it had identified cases of liver injury in patients ...

AMGN, T, and Roche shares outperform as strong drug portfolios and wireless momentum offset key headwinds like pricing pressure and legacy declines.

Biopharma company Amgen plans to add 370 jobs as part of a new, $1.02 billion investment in Holly Springs. It’s the latest move by the company to expand manufacturing capacity in the fast-growing ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit ...

Roche's strong drug growth is offsetting legacy declines, while strategic deals aim to reshape its portfolio amid biosimilar pressure and FX headwinds.

Not content with lining up one potential rival to Amgen’s Tepezza, Viridian Therapeutics has scored a phase 3 win for another thyroid eye disease (TED) prospect. But the candidate's inability to meet ...

A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to continue marketing a high dose of a pricey cancer treatment instead of a lower dose that is less expensive ...

The EMA's human medicines committee has recommended approval of Amgen's bispecific T-cell engager (BiTE) – Imdylltra – as a second-line treatment option for extensive-stage small cell lung cancer ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.